Check out how Halia Therapeutics, Inc. is approaching Parkinson’s disease and other inflammatory conditions in this article from BioSpace
Could breaking the cycle of inflammation be the next breakthrough in #Parkinson's disease? BioSpace Jill Drachenberg https://lnkd.in/gWh_jTBK
Inflammation in osteoarthritis: Our view on its presence and involvement in disease development over the years https://bit.ly/3vNfy3h #Osteoarthritis #KneeOsteoarthritis #OA
To do or not to do: rare disease edition. Placebo control is challenging, especially so in rare disease studies. When in doubt, check out our insights into this great debate: https://bit.ly/48fDk54 #PlaceboControl #RareDiseaseTrials "
Based on these data, the phase 2 Regenerate PD trial of AB-1005 will begin enrolling later this year for #Parkinson disease. https://lnkd.in/eC6P-fW5
Resmetirom shows promise in treating nonalcoholic steatohepatitis (NASH) by reducing liver fat and inflammation, potentially slowing disease progression. Read more in the latest issue of #EndocrinePractice!
Resmetirom shows promise in treating nonalcoholic steatohepatitis (NASH) by reducing liver fat and inflammation, potentially slowing disease progression. Read more in the latest issue of #EndocrinePractice!
#ICYMI...Calling all KOL's, Analysts, Patient Advocates and Investors who share a common interest in #neurodegenerativediseases. Please join us for our R&D update next Thursday. "Beyond Symptomatic Treatment of #Parkinson’s Disease: Gain Therapeutics R&D Update with KOL & Analyst Insights 2024" Date: February 22nd, 2024 Time: 11:00 am - 12:00 pm EST Register for the Event here: https://lnkd.in/erx-c4vn Send any questions you’d like answered in our Q&A to ir@gaintherapeutics.com. Discussion Topics GBA-associated Parkinson’s Disease & other Synucleinopathies: current unmet medical needs and needed therapies. From biology to classification: understanding Parkinson’s Disease. Discussion of recent in vivo data for GT-02287 as a best-in-class small molecule, for the treatment of GBA-Parkinson’s Disease and other neurodegenerative diseases. Speakers Gain Therapeutics Matthias Alder - Chief Executive Officer Joanne Taylor – Senior Vice President, Research Key Opinion Leaders Professor Roy Alcalay Prof. Alcalay is Chief of the Movement Disorders Division at Tel Aviv Sourasky Medical Center in Tel Aviv, Israel. He also holds an associate professorship in clinical neurology at Columbia University. His research focuses on biomarkers and genetics in Parkinson’s Disease. He is a member of The Michael J. Fox Foundation for Parkinson's Research-funded Parkinson’s Progression Markers Initiative (PPMI) executive steering committee, and the PI of the Parkinson’s Foundation-funded PD GENEration study. Professor Tiago Fleming Outeiro Prof. Outeiro is Professor and Director of the Department of Experimental Neurodegeneration at the University Medical Center Göttingen in Germany. He is also Professor at Newcastle University. His research interests are focused on the understanding of the molecular mechanisms of neurodegenerative diseases such as Parkinson’s, Huntington’s, and Alzheimer’s disease. He is Chair of the Task Force on the Biological Definition of Parkinson’s Disease of Internation Parkinson and Movement Disorder Society.
Researchers at Karolinska Institutet have developed scDrugPrio, a computational model for creating a "digital twin" of autoimmune diseases. This model enables personalized medication choices by analyzing cellular interactions and drug effects. This innovative approach, validated in studies on mice and patients with inflammatory bowel disease, promises to enhance treatment efficacy and reduce healthcare costs by selecting the most effective drugs for individual patients based on the disease's genetic and cellular complexities. #DigitalTwins #ComputationalModels
scDrugPrio: Revolutionizing Autoimmune Disease Treatment By Creating Digital Twins https://lnkd.in/enAEFrt7
Resmetirom shows promise in treating nonalcoholic steatohepatitis (NASH) by reducing liver fat and inflammation, potentially slowing disease progression. Read more in the latest issue of #EndocrinePractice!
Oncology ☆ Medical Science Liaison ☆ KOL Management ☆ Scientific & Medical Affairs ☆ Patient Navigation ☆ Relationship Builder ☆ Georgia Trend's 40 under 40 ☆ Yoga Enthusiast
Whether ibrutinib–venetoclax and personalization of treatment duration according to measurable residual disease (MRD) is more effective than fludarabine–cyclophosphamide–rituximab (FCR) in CLL? FLAIR phase 3 trial data: MRD-directed ibrutinib–venetoclax improved progression-free survival as compared with FCR, and results for overall survival also favored ibrutinib–venetoclax. #cll https://lnkd.in/e4g37a-3
𝗘𝘅𝗽𝗹𝗼𝗿𝗶𝗻𝗴 𝗠𝗮𝗿𝗸𝗲𝘁 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀: Fabry Disease Curious about the latest advancements in the field of Fabry Disease? Look no further! Wissen Research brings you an in-depth report that sheds light on every aspect of this disease, highlighting: #MarketInsights #ProductAnalysis #CompetitiveAnalysis #PatentAnalysis #ClinicalTrials #Treatment #OpportunityAnalysis #MarketForecast For detailed report: https://lnkd.in/gswnsHQn Request customized report: https://lnkd.in/d6q8Q-5a #marketresearch #marketreport #marketforecast #askforcustomization #wissenresearch #marketinsights #FabryDisease
